Inactivation of CYP2D6 by Berberrubine and the Chemical Mechanism

被引:0
|
作者
Rao, Jinqiu [1 ,2 ,3 ]
Wang, Tianwang [1 ,2 ,3 ]
Yu, Leran [1 ]
Wang, Kai [1 ,2 ]
Qiu, Feng [1 ,2 ,3 ]
机构
[1] Tianjin Univ Tradit Chinese Med, Sch Chinese Mat Med, Tianjin 301617, Peoples R China
[2] Tianjin Univ Tradit Chinese Med, Tianjin Key Lab Therapeut Subst Tradit Chinese Med, Tianjin 301617, Peoples R China
[3] Tianjin Univ Tradit Chinese Med, State Key Lab Component Based Chinese Med, Tianjin 301617, Peoples R China
基金
中国国家自然科学基金;
关键词
IN-VITRO; DRUG-INTERACTIONS; METABOLISM; BERBERINE; INHIBITION; PHARMACOKINETICS; BUPROPION; RELEVANCE; P450;
D O I
10.1021/acs.biochem.4c00450
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Berberrubine (BRB), belonging to the benzylisoquinoline alkaloid, is a main metabolite of berberine in vivo. BRB was previously proven to undergo metabolic activation mediated by P450s. In this study, the chemical interactions between BRB and CYP2D6 enzyme were investigated. First, a variety of P450s participated in the metabolism of berberine transformed to BRB, but CYP2D6 was the most involved enzyme. A time-, concentration-, and nicotinamide adenine dinucleotide phosphate (NADPH)-dependent inhibition of CYP2D6 was caused by BRB. The inhibitory effect of BRB on CYP2D6 was irreversible. The maximum reaction rate constants of inactivation (k inact) and half-maximal inactivation (K I) of BRB on CYP2D6 were 0.0410 min-1 and 3.798 mu M, respectively. Metoprolol, a classic substrate of CYP2D6, attenuated CYP2D6 from inactivation by BRB. Glutathione (GSH) and catalase/superoxide dismutase failed to protect against the inactivation of CYP2D6 caused by BRB. Three cys-based adducts derived from the reaction of electrophilic metabolites of BRB with CYP2D6 were detected by ultra performance liquid chromatography-mass spectrometry (UPLC-MS)/MS. The reactive metabolites derived from BRB might be responsible for the inactivation of CYP2D6. In summary, BRB was characterized as a mechanism-based inactivator of CYP2D6.
引用
收藏
页码:3078 / 3089
页数:12
相关论文
共 50 条
  • [1] Nitidine Chloride Is a Mechanism-Based Inactivator of CYP2D6
    Mao, Xu
    Hu, Zixia
    Wang, Qian
    Zhang, Na
    Zhou, Shenzhi
    Peng, Ying
    Zheng, Jiang
    DRUG METABOLISM AND DISPOSITION, 2018, 46 (08) : 1137 - 1145
  • [2] Mechanism-based CYP2D6 inactivation by acridone alkaloids of Indonesian medicinal plant Lunasia amara
    Takahashi, Naoto
    Subehan
    Kadota, Shigetoshi
    Tezuka, Yasuhiro
    FITOTERAPIA, 2012, 83 (04) : 774 - 779
  • [3] The regioselectivity of the interaction between dextromethorphan and CYP2D6
    Sun, Min-Zhang
    Zheng, Qing-Chuan
    PHYSICAL CHEMISTRY CHEMICAL PHYSICS, 2022, 24 (04) : 2234 - 2242
  • [4] Quasi-Irreversible Inhibition of CYP2D6 by Berberine
    Kim, Ha Gyeong
    Lee, Han Sol
    Jeon, Jang Su
    Choi, Young Jae
    Choi, Yeon Jung
    Yoo, So-Yeol
    Kim, Eun-yeong
    Lee, Kiho
    Park, InWha
    Na, MinKyun
    Park, Han-Jin
    Cho, Seung-Woo
    Kim, Jong-Hoon
    Lee, Jae-Young
    Kim, Sang Kyum
    PHARMACEUTICS, 2020, 12 (10) : 1 - 14
  • [5] Impact of CYP2D6 polymorphisms on the pharmacokinetics of lovastatin in Chinese subjects
    Yin, Ophelia Qi Ping
    Mak, Valiant Wah Lun
    Hu, Miao
    Fok, Benny Siu Pong
    Chow, Moses Sing Sum
    Tomlinson, Brian
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2012, 68 (06) : 943 - 949
  • [6] Assessing the Mechanism of Fluoxetine-Mediated CYP2D6 Inhibition
    Deodhar, Malavika
    Al Rihani, Sweilem B.
    Darakjian, Lucy
    Turgeon, Jacques
    Michaud, Veronique
    PHARMACEUTICS, 2021, 13 (02) : 1 - 10
  • [7] Metoclopramide is metabolized by CYP2D6 and is a reversible inhibitor, but not inactivator, of CYP2D6
    Livezey, Mara R.
    Briggs, Erran D.
    Bolles, Amanda K.
    Nagy, Leslie D.
    Fujiwara, Rina
    Furge, Laura Lowe
    XENOBIOTICA, 2014, 44 (04) : 309 - 319
  • [8] Modulation of CYP2D6 and CYP3A4 metabolic activities by Ferula asafetida resin
    Al-Jenoobi, Fahad I.
    Al-Thukair, Areej A.
    Alam, Mohd Aftab
    Abbas, Fawkeya A.
    Al-Mohizea, Abdullah M.
    Alkharfy, Khalid M.
    Al-Suwayeh, Saleh A.
    SAUDI PHARMACEUTICAL JOURNAL, 2014, 22 (06) : 564 - 569
  • [9] Human CYP2D6 Is Functional in Brain In Vivo: Evidence from Humanized CYP2D6 Transgenic Mice
    Tolledo, Cole
    Stocco, Marlaina R.
    Miksys, Sharon
    Gonzalez, Frank J.
    Tyndale, Rachel F.
    MOLECULAR NEUROBIOLOGY, 2020, 57 (06) : 2509 - 2520
  • [10] Effect of CYP2D6 genetic polymorphism on peak propafenone concentration: no significant effect of CYP2D6*10
    Doki, Kosuke
    Shirayama, Yuki
    Sekiguchi, Yukio
    Aonuma, Kazutaka
    Kohda, Yukinao
    Ieda, Masaki
    Homma, Masato
    PHARMACOGENOMICS, 2020, 21 (18) : 1279 - 1288